Emily J Cicali, Pharm.D.
Clinical Associate Professor
Department:
Pharmacotherapy & Translational Research
Business Phone:
(352) 273-7919
Business Email:
emily.cicali@cop.ufl.edu
About Emily J Cicali
Emily J. Cicali, Pharm.D., received her Doctor of Pharmacy degree from Philadelphia College of Pharmacy, University of the Sciences in 2015. She then completed a Pharmacy Practice Residency at Tabula Rasa HealthCare in Geriatric Personalized Medicine. After her residency, she was hired to work Tabula Rasa HealthCare at as a Research Pharmacist, as well as adjunct faculty at the Philadelphia College of Pharmacy, focusing on clinical pharmacokinetics and pharmacogenomics implementation. In 2017 she decided to fully transition to academia, which led to her completion of a fellowship in pharmacogenomics at the University of Florida. Cicali is now a Clinical Associate Professor in the Department of Pharmacotherapy and Translational Research. Her clinical practice is an outpatient virtual pharmacogenetics consultation service, MyRx, and her research interests include clinical implementation of pharmacogenomics as well as further understanding the role of phenoconversion for optimal medication safety.
Teaching Profile
Courses Taught
2019,2021-2025
PHA5012 App Personalized Med
2019,2021-2025
PHA5166L Prof Skills Lab Vi
2021-2025
PHA5132 Prin Drug Ther Indiv
2021
PHA5519 Advanced Topics in Anticoagulation Pharmacotherapy
Board Certifications
-
Board-certified pharmacotherapy specialist (BCPS)Board of Pharmacy Specialties
Clinical Profile
Specialties
- Pharmacy
Research Profile
Research Interests: Clinical implementation of pharmacogenomics, pharmacokinetic changes caused by CYP-inhibitors (phenoconversion, survey research to patients and prescribers to determine attitudes and acceptability of pharmacogenomics
Publications
Academic Articles
2025
The Pharmacogenomics Global Research Network Implementation Working Group: global collaboration to advance pharmacogenetic implementation.
Pharmacogenetics and genomics.
35(1):1-11
[DOI] 10.1097/FPC.0000000000000547.
[PMID] 39485373.
2024
Assessing user perspectives on clinical pharmacogenomics consultation documentation: a user-centered evaluation.
Frontiers in pharmacology.
15
[DOI] 10.3389/fphar.2024.1377132.
[PMID] 38783934.
2024
Implementation of a pharmacogenetic panel-based test for pharmacotherapy-based supportive care in an adult oncology clinic.
Clinical and translational science.
17(7)
[DOI] 10.1111/cts.13890.
[PMID] 39046302.
2024
Implementing a pragmatic clinical trial to tailor opioids for chronic pain on behalf of the IGNITE ADOPT PGx investigators.
Clinical and translational science.
17(8)
[DOI] 10.1111/cts.70005.
[PMID] 39177194.
2024
Rationale and design for a pragmatic randomized trial to assess gene-based prescribing for SSRIs in the treatment of depression.
Clinical and translational science.
17(6)
[DOI] 10.1111/cts.13822.
[PMID] 38860639.
2024
Strategies for DPYD testing prior to fluoropyrimidine chemotherapy in the US.
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer.
32(8)
[DOI] 10.1007/s00520-024-08674-1.
[PMID] 38980476.
2024
Use of CYP2D6 Inhibitors with CYP2D6 Opioids: Association with Emergency Department Visits for Pain.
Clinical pharmacology and therapeutics.
116(4):1005-1012
[DOI] 10.1002/cpt.3314.
[PMID] 38797987.
2023
A Pharmacogenetics-Based Approach to Managing Gastroesophageal Reflux Disease: Current Perspectives and Future Steps.
Pharmacogenomics and personalized medicine.
16:645-664
[DOI] 10.2147/PGPM.S371994.
[PMID] 37383676.
2023
Clinician Response to Pharmacogenetic Clinical Decision Support Alerts.
Clinical pharmacology and therapeutics.
114(6):1350-1357
[DOI] 10.1002/cpt.3051.
[PMID] 37716912.
2023
CYP2D6-guided opioid therapy for adults with cancer pain: AÂ randomized implementation clinical trial.
Pharmacotherapy.
43(12):1286-1296
[DOI] 10.1002/phar.2875.
[PMID] 37698371.
2023
Implementation of CYP2C19 genotyping to guide proton pump inhibitor use at an academic health center.
American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.
80(15):994-1003
[DOI] 10.1093/ajhp/zxad099.
[PMID] 37166240.
2023
Lessons from clinical implementation of a preemptive pharmacogenetic panel as part of a testing pilot program with an employer-sponsored medical plan.
Frontiers in genetics.
14
[DOI] 10.3389/fgene.2023.1249003.
[PMID] 37680199.
2023
Reimbursement of pharmacogenetic tests at a tertiary academic medical center in the United States.
Frontiers in pharmacology.
14
[DOI] 10.3389/fphar.2023.1179364.
[PMID] 37645439.
2022
Design and rationale of GUARDD-US: A pragmatic, randomized trial of genetic testing for APOL1 and pharmacogenomic predictors of antihypertensive efficacy in patients with hypertension.
Contemporary clinical trials.
119
[DOI] 10.1016/j.cct.2022.106813.
[PMID] 35660539.
2022
Exploring perceptions, knowledge, and attitudes regarding pharmacogenetic testing in the medically underserved.
Frontiers in genetics.
13
[DOI] 10.3389/fgene.2022.1085994.
[PMID] 36712853.
2022
How to Implement a Pharmacogenetics Service at your Institution.
Journal of the American College of Clinical Pharmacy : JACCP.
5(11):1161-1175
[DOI] 10.1002/jac5.1699.
[PMID] 36589694.
2022
Implementing a pragmatic clinical trial to tailor opioids for acute pain on behalf of the IGNITE ADOPT PGx investigators.
Clinical and translational science.
15(10):2479-2492
[DOI] 10.1111/cts.13376.
[PMID] 35899435.
2022
The importance of phenoconversion when using the CYP2D6 genotype in clinical practice.
Pharmacogenomics.
23(14):749-752
[DOI] 10.2217/pgs-2022-0087.
[PMID] 36102178.
2021
Acceptability, Feasibility, and Utility of Integrating Pharmacogenetic Testing into a Child Psychiatry Clinic.
Clinical and translational science.
14(2):589-598
[DOI] 10.1111/cts.12914.
[PMID] 33166056.
2021
Determining the potential clinical value of panel-based pharmacogenetic testing in patients with chronic pain or gastroesophageal reflux disease.
The pharmacogenomics journal.
21(6):657-663
[DOI] 10.1038/s41397-021-00244-6.
[PMID] 34075203.
2021
How to Integrate CYP2D6 Phenoconversion Into Clinical Pharmacogenetics: A Tutorial.
Clinical pharmacology and therapeutics.
110(3):677-687
[DOI] 10.1002/cpt.2354.
[PMID] 34231197.
2021
Multisite investigation of strategies for the clinical implementation of pre-emptive pharmacogenetic testing.
Genetics in medicine : official journal of the American College of Medical Genetics.
23(12):2335-2341
[DOI] 10.1038/s41436-021-01269-9.
[PMID] 34282303.
2021
The Complex Roadmap to Infectious Disease Innovation: The Intersection of Bugs, Drugs, and Special Populations.
Clinical pharmacology and therapeutics.
109(4):793-796
[DOI] 10.1002/cpt.2208.
[PMID] 33769563.
2021
Utilizing a Human-Computer Interaction Approach to Evaluate the Design of Current Pharmacogenomics Clinical Decision Support.
Journal of personalized medicine.
11(11)
[DOI] 10.3390/jpm11111227.
[PMID] 34834578.
2020
A Scoping Review of the Evidence Behind Cytochrome P450 2D6 Isoenzyme Inhibitor Classifications.
Clinical pharmacology and therapeutics.
108(1):116-125
[DOI] 10.1002/cpt.1768.
[PMID] 31910286.
2020
How to Transition from Single-Gene Pharmacogenetic Testing to Preemptive Panel-Based Testing: A Tutorial.
Clinical pharmacology and therapeutics.
108(3):557-565
[DOI] 10.1002/cpt.1912.
[PMID] 32460360.
2020
Precision medication: An illustrative case series guiding the clinical application of multi-drug interactions and pharmacogenomics.
Clinical case reports.
8(2):305-312
[DOI] 10.1002/ccr3.2604.
[PMID] 32128178.
2019
Challenges and lessons learned from clinical pharmacogenetic implementation of multiple gene-drug pairs across ambulatory care settings.
Genetics in medicine : official journal of the American College of Medical Genetics.
21(10):2264-2274
[DOI] 10.1038/s41436-019-0500-7.
[PMID] 30926959.
2019
IGNITE network: Response of patients to genomic medicine interventions.
Molecular genetics & genomic medicine.
7(5)
[DOI] 10.1002/mgg3.636.
[PMID] 30895746.
2019
Novel Implementation of Genotype-Guided Proton Pump Inhibitor Medication Therapy in Children: A Pilot, Randomized, Multisite Pragmatic Trial.
Clinical and translational science.
12(2):172-179
[DOI] 10.1111/cts.12589.
[PMID] 30341969.
2018
Implementation of a pharmacist-led pharmacogenomics service for the Program of All-Inclusive Care for the Elderly (PHARM-GENOME-PACE).
Journal of the American Pharmacists Association : JAPhA.
58(3):281-289.e1
[DOI] 10.1016/j.japh.2018.02.011.
[PMID] 29602745.
2017
Implementation of a Standardized Medication Therapy Management Plus Approach within Primary Care.
Journal of the American Board of Family Medicine : JABFM.
30(6):701-714
[DOI] 10.3122/jabfm.2017.06.170145.
[PMID] 29180545.
2017
Reducing Off-Label Antipsychotic Use in Older Community-Dwelling Adults With Dementia: A Narrative Review.
The Journal of the American Osteopathic Association.
117(7):441-450
[DOI] 10.7556/jaoa.2017.090.
[PMID] 28662557.
2017
The Role of Hospital Pharmacists in the Adoption and Use of Pharmacogenomics and Precision Medicine
Personalized Medicine.
14(1):27-35
Grants
Sep 2021
– Aug 2023
Warfarin Pharmacogenetics at UF Health
Role: Principal Investigator
Funding: UF HEALTH SHANDS HOSPITAL
Jul 2019
– Jun 2022
Expansion of the Phamacogentics (PGx) Consultation Clinic to Family Medicine
Role: Principal Investigator
Funding: UF HEALTH SHANDS HOSPITAL
Education
Postdoctoral Fellowship in Pharmacogenomics
2017-2018
·
University of Florida
PGY1 Pharmacy Residency: Geriatric Personalized Medicine & Targeted Therapeutics
2015-2016
·
CareKinesis Inc.
Pharm.D.
2015
·
Philadelphia College of Pharmacy
B.S.
2013
·
Philadelphia College of Pharmacy
Contact Details
Phones:
- Business:
- (352) 273-7919
Emails:
- Business:
- emily.cicali@cop.ufl.edu
Addresses:
- Business Mailing:
-
PO Box 100486
GAINESVILLE FL 32610 - Business Street:
-
1600 SW ARCHER RD
HPNP 2336
GAINESVILLE FL 32610